A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Phase 3
55
about 1.6 years
10–17
41 sites in AR, AZ, CA +23
About this study
Researchers are testing different doses of dulaglutide in children with type 2 diabetes. The trial will last about 8 months.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dulaglutide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dulaglutide
Primary: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Secondary: Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Total Cholesterol, Change from Baseline in the EQ-5D-Y-5L, PK: Maximum Observed Concentration (Cmax) of Dulaglutide, Percent Change from Baseline in Body Weight, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Dulaglutide
Endocrinology